$70.93 Million in Sales Expected for Sarepta Therapeutics Inc (SRPT) This Quarter

Equities analysts expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report sales of $70.93 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from $69.00 million to $73.22 million. Sarepta Therapeutics posted sales of $35.01 million in the same quarter last year, which suggests a positive year-over-year growth rate of 102.6%. The company is expected to announce its next earnings report on Wednesday, July 18th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $298.22 million for the current fiscal year, with estimates ranging from $285.40 million to $308.66 million. For the next year, analysts expect that the business will report sales of $436.01 million per share, with estimates ranging from $362.54 million to $519.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The business had revenue of $64.60 million for the quarter, compared to the consensus estimate of $65.31 million. During the same period in the prior year, the business posted ($0.57) EPS. Sarepta Therapeutics’s revenue for the quarter was up 295.3% on a year-over-year basis.

A number of equities analysts have weighed in on SRPT shares. SunTrust Banks raised their target price on shares of Sarepta Therapeutics to $95.00 and gave the company a “buy” rating in a research note on Friday, March 16th. HC Wainwright reaffirmed a “buy” rating and set a $92.00 target price on shares of Sarepta Therapeutics in a research note on Monday, April 23rd. Royal Bank of Canada reaffirmed a “buy” rating and set a $91.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, March 14th. Credit Suisse Group set a $100.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 5th. Finally, ValuEngine raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $147.98.

Shares of NASDAQ SRPT traded down $0.31 on Friday, reaching $137.73. 656,496 shares of the company’s stock traded hands, compared to its average volume of 1,646,908. Sarepta Therapeutics has a 12 month low of $32.80 and a 12 month high of $176.50. The company has a market capitalization of $9.04 billion, a price-to-earnings ratio of -83.93 and a beta of 1.34. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.

In related news, Director Richard Barry sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total value of $9,775,500.00. Following the sale, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of SRPT. Element Capital Management LLC purchased a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $17,706,000. Frontier Capital Management Co. LLC purchased a new stake in Sarepta Therapeutics in the first quarter worth approximately $16,940,000. JPMorgan Chase & Co. boosted its holdings in Sarepta Therapeutics by 36.3% in the first quarter. JPMorgan Chase & Co. now owns 709,070 shares of the biotechnology company’s stock worth $52,535,000 after purchasing an additional 188,841 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $9,209,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $8,295,000. Institutional investors own 86.27% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit